Biostem Technologies, Inc. (NASDAQ:BSEM) Sees Significant Decline in Short Interest

Biostem Technologies, Inc. (NASDAQ:BSEM) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 119,203 shares, a drop of 78.5% from the August 15th total of 554,233 shares. Based on an average trading volume of 89,169 shares, the short-interest ratio is currently 1.3 days. Approximately 0.7% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BSEM. Weiss Ratings started coverage on shares of Biostem Technologies in a report on Wednesday, August 19th. They issued a “sell (d-)” rating for the company. Wall Street Zen raised shares of Biostem Technologies to a “sell” rating in a research note on Saturday, September 5th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Biostem Technologies Price Performance

Shares of Biostem Technologies stock opened at $4.18 on Friday. Biostem Technologies has a one year low of $2.25 and a one year high of $8.40. The business’s 50 day simple moving average is $3.62 and its two-hundred day simple moving average is $4.46. The stock has a market capitalization of $74.61 million, a P/E ratio of -2.61 and a beta of 0.12.

About Biostem Technologies

BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.

Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.